The Case for Early Initiation of Monotherapies and Delayed Dopaminergic Therapy in Parkinson's Disea
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug
2
GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis
3
Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care
4
MDS/MPN Response Criteria Tied to Survival
5